Fosifloxuridine Nafalbenamide
Head And Neck Squamous Cell Carcinoma
Explore 249 assets in Head And Neck Squamous Cell Carcinoma →Floatz Rating
C35/100
Confidence
Indicative
Sponsor
NuCana plc
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
25Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05714553CT.gov NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Head And Neck Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fosifloxuridine Nafalbenamide (this asset) | NuCana plc | P1/2 | C · 35 |
| Cis-Diamminedichloroplatinum Ii | Akeso | P3 | BB |
| Carboplatin | Akeso | P4 | BB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P4 | BB |
| Pembrolizumab | UNC Lineberger Comprehensive Cancer Center | P4 | BB |
| Irinotecan | Neonc Technologies, Inc. | P2 | BB |
| Capecitabine | Merck Sharp & Dohme LLC | P2 | BB |
| Tisotumab Vedotin | Seagen, a wholly owned subsidiary of Pfizer | P2 | B |
| Etoposide | M.D. Anderson Cancer Center | P1/2 | B |
+42 more in the Head And Neck Squamous Cell Carcinoma cohort
Other indications for Fosifloxuridine Nafalbenamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Neoplasm | — | P2 | CC · 44 |
| Cancer | — | P1/2 | CC · 42 |
| Squamous Cell Carcinoma | — | P1/2 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fosifloxuridine Nafalbenamide in Head And Neck Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fosifloxuridine-nafalbenamide-head-and-neck-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →